Naratriptan Teva (Naratriptan Hydrochloride)

Naratriptan selectively activates serotonin 5‑HT1B and 5‑HT1D receptors, causing constriction of dilated cranial blood vessels and inhibition of trigeminal nerve release of pain‑mediating neuropeptides, which helps stop a migraine attack.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual patient's needs and medical history. Patients should follow the prescriber’s instructions exactly.

Safety data for Naratriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics. Compared with other triptans, it has a longer half‑life, which may allow a single dose to be effective for many patients, but individual response varies.

Store Naratriptan tablets at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed and protect it from moisture and direct sunlight to maintain product stability.

Naratriptan is taken orally, usually as a tablet, with or without water. It should be taken as soon as possible after the onset of migraine symptoms, following the dosage instructions provided by the prescriber.

Serious risks include chest pain or cardiac ischemia, severe hypertension, serotonin syndrome when combined with other serotonergic agents, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if any of these occur.

Naratriptan is contraindicated in patients with uncontrolled hypertension, significant cardiovascular disease (including coronary artery disease, history of myocardial infarction, or stroke), peripheral vascular disease, or known hypersensitivity to the drug or any of its excipients.